AI > AI + Human > Human: healthcare's most uncomfortable finding yet

“I try to buy stock in businesses that are so wonderful that an idiot can run them. Because sooner or later, one will.”

— WARREN BUFFETT, Chairman & CEO, Berkshire Hathaway

AI's clinical and operational capability is outrunning the humans meant to supervise it. A new JAMA argument says oversight itself can degrade outcomes. Epic is shipping AI faster than systems can absorb it. And a Mayo model just outperformed expert echocardiographers on the same images. The technology is no longer the limit.

Ezekiel Emanuel and colleagues argue autonomous AI may outperform physicians, even those AI-assisted. Their provocation: human oversight can worsen outcomes once AI surpasses clinicians, via algorithm aversion and deskilling. Evidence leans on simulations, and liability, reimbursement, and physical-procedure gaps remain. Still, it reframes human-in-the-loop from safeguard to potential liability. JAMA

At Epic's UGM, CIOs described a blistering release pace: Agent Factory for custom agents, Cosmos-driven predictions, and the Ergo AI visit. The worry is not capability but absorption. Epic now ships more each quarter than it once did in 18 months, straining governance, training, and token budgets. The bottleneck is human. Becker's Hospital Review

Mayo Clinic built and externally validated an AI model that flags LVOT obstruction in hypertrophic cardiomyopathy from routine B-mode ultrasound, no Doppler required. Trained on 1,833 patients and validated in South Korea, it beat two expert echocardiographers on the same images in a subset. Access, not replacement, is the point. Newswise

All 14 large systems grew Q2 revenue, yet margins ran from AdventHealth's 13.4% to Essentia's 0.5%. Providence is exiting insurance after its Medicare Advantage deal collapsed. Costco is walking the other way, into Medicare Advantage. Scale is common. Conversion is rare.

All 14 large systems grew Q2 revenue year over year, but margins split hard. AdventHealth hit 13.4% and Scripps doubled to 6.6%, while Providence (0.8%), Mass General Brigham (1.3%), and Essentia (0.5%) stayed razor-thin. Kaiser's scale delivered $1.7 billion in operating income. Growth is universal; conversion is not. Becker's Hospital Review

Providence's Medicare Advantage transfer to a national carrier collapsed, turning a partial retreat into a full wind-down of its 435,000-member health plan by 2027. The regional nonprofit lost $102 million in 2025 as scaled insurers squeezed it out. Provider-sponsored plans are folding just as Costco moves in. Becker's Payer

Costco is piloting co-branded Medicare Advantage in two states and a supplement in a third, partnering with nonprofit SCAN Group pending CMS approval. The bet is trust as distribution: Costco vets what it sells, and members extend that to insurance. It arrives as CVS and Walgreens retreat from retail health. New York Post

Capital is repricing what it thinks is scarce. Stripe paid a reported $7.5 billion for the layer that meters AI tokens. Anthropic is preparing an IPO to rival SpaceX at a $965 billion valuation. And Moderna's stock more than doubled on the first Phase 3 win for a personalized cancer vaccine. Value is flowing to the meter and the moat.

Stripe is acquiring OpenRouter, the gateway routing traffic across 400-plus models, for a reported $7.5 billion, roughly 6x its $1.3 billion valuation three months ago. The prize is not routing; it is the meter. Whoever counts and bills AI tokens owns the spend relationship. Ramp is reportedly building its own router too. Stripe

Anthropic confidentially filed a draft S-1 and aims to match or top SpaceX's $86 billion IPO, the largest ever, possibly filing publicly within weeks. It follows a May round valuing the Claude maker at $965 billion despite a $42 billion 2025 net loss. AI capital formation shows no ceiling. Bloomberg

Moderna and Merck's personalized mRNA vaccine, intismeran, plus Keytruda cut melanoma recurrence and distant spread versus Keytruda alone in the first Phase 3 for a neoantigen vaccine. Across 1,137 post-surgical patients, it validated mRNA beyond COVID. Moderna stock soared past 100%. Next test: manufacturing a custom vaccine per patient. STAT News

The economy is downshifting: growth slowed to 1.5% and payrolls turned negative, even as inflation cooled to 3.4%. Oil and long-term yields are climbing, yet equities keep pushing higher, up 12.6% year to date.

Values as of Aug 20, 2026. Market metrics (WTI, 10-year, S&P 500) to refresh at Friday close. Teal favorable, red unfavorable. Sources: BEA, BLS, market data.